Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma

Media coverage

• Title	Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	Market News Publishing
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	India Pharma News
  Country	India
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	Yahoo! Finance
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	MarketScreener.com
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	Jotup
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	BioSpace
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	Biotechgate
  Country	Switzerland
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT„¢ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	PrimeNewswire (Top News)
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	GlobeNewswire
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner

• Title	Plus Therapeutics Announces Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma
  Media name/outlet	Newbridge Securities Corporation
  Country	United States
  Date	11/19/20
  Persons	Andrew Brenner